JP2023511756A5 - - Google Patents
Info
- Publication number
- JP2023511756A5 JP2023511756A5 JP2022546432A JP2022546432A JP2023511756A5 JP 2023511756 A5 JP2023511756 A5 JP 2023511756A5 JP 2022546432 A JP2022546432 A JP 2022546432A JP 2022546432 A JP2022546432 A JP 2022546432A JP 2023511756 A5 JP2023511756 A5 JP 2023511756A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- extracellular protein
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968802P | 2020-01-31 | 2020-01-31 | |
| US62/968,802 | 2020-01-31 | ||
| US202063063015P | 2020-08-07 | 2020-08-07 | |
| US63/063,015 | 2020-08-07 | ||
| PCT/US2021/015939 WO2021155317A1 (en) | 2020-01-31 | 2021-01-29 | Asgpr-binding compounds for the degradation of extracellular proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511756A JP2023511756A (ja) | 2023-03-22 |
| JP2023511756A5 true JP2023511756A5 (cg-RX-API-DMAC7.html) | 2024-02-06 |
| JP7849881B2 JP7849881B2 (ja) | 2026-04-22 |
Family
ID=77079267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546432A Active JP7849881B2 (ja) | 2020-01-31 | 2021-01-29 | 細胞外タンパク質を分解するａｓｇｐｒ結合性化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US11819551B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4097138A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7849881B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230006800A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115066438A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021213822A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022014522A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3162687A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294515A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009419A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202142231A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021155317A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230097887A1 (en) | 2018-04-09 | 2023-03-30 | Yale University | Bi-functional Molecules to Degrade Circulating Proteins |
| EP3773727A4 (en) | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
| US12485178B2 (en) | 2018-04-09 | 2025-12-02 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| KR20220099963A (ko) * | 2019-10-10 | 2022-07-14 | 예일 유니버시티 | 세포 수용체를 통한 분자 분해제로서의 조작된 항체 |
| EP4041262A4 (en) * | 2019-10-10 | 2024-03-13 | Yale University | Targeted bifunctional degraders |
| WO2021155317A1 (en) * | 2020-01-31 | 2021-08-05 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the degradation of extracellular proteins |
| WO2022035997A1 (en) * | 2020-08-11 | 2022-02-17 | Avilar Therapeutics, Inc. | In vivo assembly of asgpr binding therapeutics |
| KR20240017423A (ko) * | 2021-05-03 | 2024-02-07 | 아빌라 테라퓨틱스, 인크. | 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물 |
| EP4370157A1 (en) | 2021-07-14 | 2024-05-22 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| WO2023009554A1 (en) * | 2021-07-26 | 2023-02-02 | Avilar Therapeutics, Inc. | Methods to reduce adverse effects of gene or biologics therapy |
| JP2024532362A (ja) * | 2021-08-27 | 2024-09-05 | イエール ユニバーシティ | 細胞外タンパク質の分子分解誘導剤 |
| WO2023028590A1 (en) | 2021-08-27 | 2023-03-02 | Yale University | Molecular degraders of extracellular proteins |
| WO2023028338A2 (en) * | 2021-08-27 | 2023-03-02 | Avilar Therapeutics, Inc. | Mannose 6-phosphate or asgpr receptor binding compounds for the degradation of extracellular proteins |
| IL315579A (en) * | 2022-03-15 | 2024-11-01 | Univ Yale | Small bifunctional compounds to target selective degradation of circulating proteins |
| KR20250004953A (ko) * | 2022-03-15 | 2025-01-08 | 예일 유니버시티 | 순환하는 단백질을 분해하기 위한 이-작용성 분자 |
| EP4611818A2 (en) * | 2022-11-03 | 2025-09-10 | Avilar Therapeutics, Inc. | Asgpr-binding heterobifunctional compounds for the degradation of immunoglobulins |
| EP4651902A2 (en) * | 2023-01-18 | 2025-11-26 | Lycia Therapeutics, Inc. | Asgpr binding compounds and conjugates |
| CN116492462B (zh) * | 2023-02-03 | 2023-09-22 | 山东第一医科大学附属眼科医院(山东省眼科医院) | Pad4抑制剂在防治角膜移植术后免疫排斥反应中的应用 |
| WO2024182772A2 (en) * | 2023-03-02 | 2024-09-06 | Avilar Therapeutics, Inc. | Mannose 6-phosphate receptor binding compounds for the degradation of extracellular proteins |
| WO2025064721A1 (en) * | 2023-09-19 | 2025-03-27 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the delivery of oligonucleotides |
| WO2025199466A1 (en) | 2024-03-22 | 2025-09-25 | Purdue Research Foundation | Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use |
| WO2025210538A1 (en) | 2024-04-02 | 2025-10-09 | Biohaven Therapeutics Ltd. | Bifunctional degraders |
| WO2025235797A1 (en) * | 2024-05-09 | 2025-11-13 | Avilar Therapeutics, Inc. | Potent asgpr-binding heterobifunctional compounds comprising antibodies for the degradation of targeted proteins |
| WO2025248469A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | TREATMENT OF IgG-RELATED DISEASES |
| WO2026028158A1 (en) | 2024-07-31 | 2026-02-05 | Biohaven Therapeutics Ltd. | Targeted degradation of anti-aav antibodies to enable aav-based gene therapy |
| WO2026028159A1 (en) | 2024-07-31 | 2026-02-05 | Biohaven Therapeutics Ltd. | Bifunctional degraders for the treatment of graves' disease |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ214774A (en) | 1986-01-08 | 1989-10-27 | Nz Scientific & Ind Res | Herbicidal and/or plant growth regulatory compositions based on 1,6-anhydro-beta-hexopyranose derivatives and certain of these derivatives |
| US5554386A (en) | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
| GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| US5624896A (en) | 1992-06-09 | 1997-04-29 | Neorx Corporation | Clearing agents useful in pretargeting methods |
| EP0646019B9 (en) | 1992-06-09 | 2002-12-18 | Neorx Corporation | Biotin-DOTA conjugates and their use in pretargeting methods |
| US5886143A (en) | 1994-12-07 | 1999-03-23 | Neorx Corporation | Hepatic-directed compounds and reagents for preparation thereof |
| US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
| US5571796A (en) * | 1995-06-06 | 1996-11-05 | Alberta Research Council | Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising from exposure to an antigen |
| ATE458499T1 (de) | 1995-06-07 | 2010-03-15 | Immunomedics Inc | Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort |
| AUPR079700A0 (en) | 2000-10-17 | 2000-11-09 | Alchemia Pty Ltd | Combinatorial libraries of monosaccharides |
| AUPS143402A0 (en) | 2002-03-28 | 2002-05-09 | Alchemia Pty Ltd | Anomeric derivatives of monosaccharides |
| US8440191B2 (en) | 2005-11-18 | 2013-05-14 | Tufts Medical Center | Clearance of abnormal IGA1 in IGA1 deposition diseases |
| WO2007070947A1 (en) | 2005-12-22 | 2007-06-28 | Alchemia Ltd | Antibacterial agents |
| WO2009041037A1 (ja) | 2007-09-26 | 2009-04-02 | Japan As Represented By The President Of National Cardiovascular Center | 体内に存在する病因物質の低下剤 |
| GB0916749D0 (en) | 2009-09-23 | 2009-11-04 | Mologic Ltd | Peptide cleaning agents |
| JP6271251B2 (ja) | 2011-10-05 | 2018-01-31 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| ES2824026T3 (es) * | 2013-05-03 | 2021-05-11 | Univ Yale | Compuestos miméticos de anticuerpos sintéticos (SyAM) dirigidos al cáncer, especialmente cáncer de próstata |
| SG11201606761RA (en) | 2014-02-21 | 2016-09-29 | Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| WO2015143091A1 (en) | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| PL3145934T3 (pl) | 2014-05-19 | 2021-08-16 | Pfizer Inc. | Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| CA3205824A1 (en) | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| CA2947904A1 (en) * | 2015-11-12 | 2017-05-12 | Pfizer Inc. | Tissue-specific genome engineering using crispr-cas9 |
| WO2017212019A1 (en) | 2016-06-09 | 2017-12-14 | Centre National De La Recherche Scientifique (Cnrs) | Raav with chemically modified capsid |
| HUE056289T2 (hu) | 2017-02-08 | 2022-02-28 | Adc Therapeutics Sa | Pirrolobenzodiazepin-antitest konjugátumok |
| CN120330183A (zh) | 2017-06-02 | 2025-07-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| EP3694530A4 (en) * | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| WO2019199621A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| EP3773727A4 (en) * | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
| US12485178B2 (en) | 2018-04-09 | 2025-12-02 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| US20230097887A1 (en) | 2018-04-09 | 2023-03-30 | Yale University | Bi-functional Molecules to Degrade Circulating Proteins |
| AU2019404061A1 (en) | 2018-12-19 | 2021-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
| KR20220099963A (ko) | 2019-10-10 | 2022-07-14 | 예일 유니버시티 | 세포 수용체를 통한 분자 분해제로서의 조작된 항체 |
| EP4041262A4 (en) | 2019-10-10 | 2024-03-13 | Yale University | Targeted bifunctional degraders |
| US20230158155A1 (en) | 2020-01-10 | 2023-05-25 | Lycia Therapeutics, Inc. | Cell Surface Receptor Binding Compounds and Conjugates |
| WO2021155317A1 (en) * | 2020-01-31 | 2021-08-05 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the degradation of extracellular proteins |
| WO2021156792A1 (en) | 2020-02-07 | 2021-08-12 | Novartis Ag | Targeted plasma protein degradation |
| US20240270780A1 (en) | 2020-04-29 | 2024-08-15 | Tai Bi Di Pharmaceutical Technology (Shijiazhuang) Co. Ltd | Proteolysis targeting compound with tissue targeting capability and use thereof |
| MX2022014606A (es) | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas. |
| EP4171658A4 (en) | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | Modified viral compositions for viral transduction |
| EP4171659A4 (en) | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | BIFUNCTIONAL BRIDGE COMPOSITIONS FOR VIRAL TRANSDUCTION |
| EP4232455A2 (en) | 2020-10-20 | 2023-08-30 | Sanofi | Novel ligands for asialoglycoprotein receptor |
| KR20240017423A (ko) | 2021-05-03 | 2024-02-07 | 아빌라 테라퓨틱스, 인크. | 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물 |
| EP4370157A1 (en) | 2021-07-14 | 2024-05-22 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| JP2024532362A (ja) | 2021-08-27 | 2024-09-05 | イエール ユニバーシティ | 細胞外タンパク質の分子分解誘導剤 |
-
2021
- 2021-01-29 WO PCT/US2021/015939 patent/WO2021155317A1/en not_active Ceased
- 2021-01-29 BR BR112022014522A patent/BR112022014522A2/pt not_active Application Discontinuation
- 2021-01-29 AU AU2021213822A patent/AU2021213822A1/en active Pending
- 2021-01-29 JP JP2022546432A patent/JP7849881B2/ja active Active
- 2021-01-29 CA CA3162687A patent/CA3162687A1/en active Pending
- 2021-01-29 EP EP21748470.8A patent/EP4097138A4/en active Pending
- 2021-01-29 MX MX2022009419A patent/MX2022009419A/es unknown
- 2021-01-29 CN CN202180012056.7A patent/CN115066438A/zh active Pending
- 2021-01-29 KR KR1020227029628A patent/KR20230006800A/ko active Pending
- 2021-01-29 IL IL294515A patent/IL294515A/en unknown
- 2021-02-01 TW TW110103726A patent/TW202142231A/zh unknown
-
2022
- 2022-07-29 US US17/877,538 patent/US11819551B2/en active Active
-
2023
- 2023-07-11 US US18/220,708 patent/US12076408B2/en active Active
-
2024
- 2024-02-22 US US18/584,914 patent/US12128106B2/en active Active
- 2024-05-02 US US18/653,610 patent/US12290568B2/en active Active
- 2024-05-02 US US18/653,655 patent/US12280116B2/en active Active
-
2025
- 2025-03-17 US US19/081,876 patent/US20250213699A1/en active Pending
- 2025-04-28 US US19/192,108 patent/US20250339541A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511756A5 (cg-RX-API-DMAC7.html) | ||
| JP6904970B2 (ja) | Ｂ型肝炎抗ウイルス剤 | |
| ES2554615T3 (es) | Amidas sustituidas, método de preparación y utilización como inhibidores de Btk | |
| JP7465945B2 (ja) | Ｂｅｔ阻害剤としてのヘテロ環式化合物 | |
| KR102782200B1 (ko) | 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드 | |
| KR20220009420A (ko) | Pd-l1 질환의 치료를 위한 트리아릴 화합물 | |
| RU2013156827A (ru) | Ингибиторы активности киназы lrrk2 | |
| JP2014506599A5 (cg-RX-API-DMAC7.html) | ||
| RU2006127396A (ru) | Пирролотриазиновые соединения как ингибиторы киназ | |
| JP2009544620A (ja) | 自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト | |
| NZ259114A (en) | Pyrazolopyrimidines and pharmaceutical compositions thereof | |
| CA2782720A1 (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| CA3152117A1 (en) | Highly active anti-neoplastic and anti-proliferative agents | |
| JP2010523497A (ja) | アデノシンａ２ａ受容体拮抗薬 | |
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| KR20120054642A (ko) | 신경자극성 피페라진의 합성방법 | |
| RU98112237A (ru) | Новые производные индол-2,3-дион-3-оксима | |
| JP2008509955A5 (cg-RX-API-DMAC7.html) | ||
| AU2019286531B2 (en) | Pyrazole and imidazole compounds for inhibition of IL-17 and rorgamma | |
| WO2022217118A1 (en) | Pyrimidine based ras modulators and uses thereof | |
| JP2016522240A (ja) | ＲＯＲｃモジュレーターとしてのアリールスルタム誘導体 | |
| RU2006124513A (ru) | Производные бензоксазина и их применение | |
| CA1238046A (en) | Dihydropyridyl cyclic imidate esters and their pharmaceutical use | |
| ES2328654A1 (es) | Compuestos de indolsufonamida sustituidos, su preparacion y uso como medicamentos. | |
| ES2649905T3 (es) | Derivado de ácido (2-heteroarilamino)succínico |